All issues
Volume 47, Issue 3
Displaying 1-10 of 10 articles from this issue
- |<
- <
- 1
- >
- >|
-
[in Japanese]2004 Volume 47 Issue 3 Pages 193-195
Published: March 30, 2004
Released on J-STAGE: March 02, 2011
JOURNAL FREE ACCESSDownload PDF (463K) -
Masanori Iwase, Sakae Nohara, Nobuhiro Sasaki, Toshitaka Himeno, Marik ...2004 Volume 47 Issue 3 Pages 197-201
Published: March 30, 2004
Released on J-STAGE: March 02, 2011
JOURNAL FREE ACCESSWe conducted pharmacokinetic studies after oral administration of 250 mg metformin to reexamine its dose-setting in Japan, where the maximum dose is limited to 750 mg daily.Tmax was 4 hrs in healthy controls (n=6) and diabetic patients (n=5).Cmax was 0.54±0.15μg/ml in control and 0.85±0.19 μg/ml in diabetic patients, consistent with data reported in the English literature.In repetitive administration of 500 mg metformin daily for 7 days, serum concentration of metformin reached the steady state on day 3, and the profile of metformin concentration on day 7 fitted well with the concentration curve predicted by that on day 1.No significantdifferences were seen in Tmax, Cmax, or T1/2 on days 1 and 7.We report the pharmacokinetics of metformin at the dose set in Japan.View full abstractDownload PDF (765K) -
Koichiro Azuma, Akira Shimada, Takao Saruta2004 Volume 47 Issue 3 Pages 203-207
Published: March 30, 2004
Released on J-STAGE: March 02, 2011
JOURNAL FREE ACCESSSulfonylureas, antidiabetic agents that act on the pancreas to stimulate insulin secretion, are known to cause weight gain.Glimepiride, a new sulfonylurea, is supposed to have extrapancreatic effects, leading to less weight gain.We compared the effect of glimepiride on weight change, glycemic control, blood pressure, and lipid metabolism, to that of gliclazide, a conventional sulfonylurea.Twenty-four (M 16/F8) overweight to obese (BMI 25.4±2.9) type 2 diabetic (FPG 192±30mg/dl, IRI 11±7μU/ml, HbA1c 8.5±0.9%) subjects were divided into 2 groups, 1 taking glimepirideand the other gliclazide, and followed up for 4 months.The 0.4kg weight gain in the glimepiride group (n=13) was significantly lower than that in the gliclazide group (n=11, p<0.01).The degree of improvement in HbA1c, blood pressure, and lipid parameter did not differ between groups.Glimepiride was therefore at least superiorto gliclazide regarding weight change in Japanese overweight to obese type 2 diabetics, although follow-up was relatively short.View full abstractDownload PDF (678K) -
Existence of Fulminant Type 1 Diabetes MellitusHiroko Takaike, Yasuko Uchigata, Asako Satoh, Junnosuke Miura, Maki Ok ...2004 Volume 47 Issue 3 Pages 209-216
Published: March 30, 2004
Released on J-STAGE: March 02, 2011
JOURNAL FREE ACCESSType 1 diabetes mellitus is classified as autoimmune or idiopathic. Rapid-onset type 1 diabetes with pancreatic exocrine dysfunction was defined as fulminant type 1 diabetes mellitus in Japan. We studied the clinical characteristics of 108 patients diagnosed with type 1 diabetes during 13 years and found fulminant type 1diabetes. When onset HbA1c was lower, patients tended to have higher blood glucose (p<0.001), higher age (p<0.05), and lower logarithmic urinary C-peptide (p<0.0001). We studied the GAD antibody in 98 patients.Of these, 13 had negative GAD antibodyand HbA1c of less than 8.5%, suspected to be f-ulminant type 1 diabetes. One patient had diabetic ketoacidosis 6 days after acute pancreatitis onset, 5 did not show increased serum pancreatic amylase, and 1 showed a slight IA-2 antibody increase.Of the 11 with fulminant type 1 diabetes, 9 had HLA DRB 1*0405-DQB 1*0401, as a haplotype susceptible to Japanese type 1 diabetes, and this haplotype may be related to this subtype. More cases should thus be studied to clarify the mechanism behind fulminant type 1 diabetes.View full abstractDownload PDF (1020K) -
[in Japanese], [in Japanese], [in Japanese], [in Japanese]2004 Volume 47 Issue 3 Pages 217-220
Published: March 30, 2004
Released on J-STAGE: March 02, 2011
JOURNAL FREE ACCESS -
[in Japanese], [in Japanese], [in Japanese], [in Japanese], [in Japane ...2004 Volume 47 Issue 3 Pages 221-225
Published: March 30, 2004
Released on J-STAGE: March 02, 2011
JOURNAL FREE ACCESS -
Toshihiro Kojima, Mayumi Yamamoto, Keigo Yasuda2004 Volume 47 Issue 3 Pages 227-232
Published: March 30, 2004
Released on J-STAGE: March 02, 2011
JOURNAL FREE ACCESSWe report a case of a 73-year-old woman with a TSH-producing pituitary adenoma whose diabetic glucose intolerance improved after the adenoma was completely resected.She reported sweating, diarrhea, and weight loss and had elevated FT3, FT4, TSH, and α-subunit serum lebels.MM findings of the brain showed an 8× 8mm tumor in the anterior pituitary lobe, which we diagnosed as a pituitary TSH-producing adenoma.Transsphenoidal adenomectomy and bromocriptine administration were not successful because thyroid function was not normalized.Reoperation completely extirpated the adenoma, achieving euthyroidism. Glucose intolerance determined at 75gOGTT before operation was normalized after reoperation.The insulin resistance evaluated with HOMA-R and glucose-or glucagon-stimulated insulin secretion was not significantly changed before or after the adenoma was resected, showing that glucose tolerance was impaired in the TSH-producing adenoma during increased serum thyroid hormone levels, as in other thyrotoxicosis.View full abstractDownload PDF (1832K) -
[in Japanese], [in Japanese], [in Japanese]2004 Volume 47 Issue 3 Pages 233-237
Published: March 30, 2004
Released on J-STAGE: March 02, 2011
JOURNAL FREE ACCESS -
[in Japanese], [in Japanese], [in Japanese], [in Japanese], [in Japane ...2004 Volume 47 Issue 3 Pages 239-245
Published: March 30, 2004
Released on J-STAGE: March 02, 2011
JOURNAL FREE ACCESS -
2004 Volume 47 Issue 3 Pages 247-263
Published: March 30, 2004
Released on J-STAGE: March 02, 2011
JOURNAL FREE ACCESSDownload PDF (3806K)
- |<
- <
- 1
- >
- >|